Synthesis and Evaluation of Novel Prodrugs of Foscarnet and Dideoxycytidine with a Universal Carrier Compound Comprising a Chemiluminescent and a Photochromic Conjugate

Journal of Pharmaceutical Sciences

Volumn 93, Issue 5, 2004, Pages 1320-1336

  Mills, Randell ^a   Wu, Guo Zhang ^a  

^a Luminide Pharmaceutical Corporation   (United States)

Author keywords

Anti HIV; Chemiluminescence; Dideoxycytidine; Foscarnet; Intermolecular energy transfer; Oxygen free radicals; Photochromism; Prodrug

Indexed keywords

DRUG CARRIER; FOSCARNET; OXYGEN RADICAL; PRODRUG; ZALCITABINE;

ACUTE TOXICITY; ARTICLE; CHEMOLUMINESCENCE; CONJUGATE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG SCREENING; DRUG SYNTHESIS; ENERGY TRANSFER; FRIEND LEUKEMIA VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROPHILICITY; LIPOPHILICITY; MACROPHAGE; RETROVIRUS;

EID: 1942434653     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20026     Document Type: Article

References (26)

1. Gaub J, Pedersen C, Poulsen AG, Mathiesen LR, Ulrich K, Lindhardt BO, Faber V, Gerstoft J, Hofmann B, Lernestedt JO, et al. 1987. The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets, and lymphocyte function. AIDS 1(1):27-33.
2. Szoka FC, Jung CC. 1989. Pharmaceutical liposomes containing phosphorous compounds for the treatment of viral infections. WO 8905152.
3. Hostetler KY, Kumar R. 1995. Lipid derivatives of phosphonacids for liposomal incorporation and method of use. US 5463092.
4. Hostetler KY, Mellors JW. 2000. Phosphonoformate lipid analogs for the treatment of drug-resistant human immunodeficiency virus infection. WO 2001047511.
5. Kini GD, Beadle JR, Xie H, Aldern KA, Richman DD, Hostetler KY. 1997. Alkoxy propane prodrugs of foscarnet: Effect of alkyl chain length on in vitro antiviral activity in cells infected with HIV-1, HSV-1, and HCMV. Antiviral Res 36(1):43-53.
6. Herrmann D, Opitz H, Zilch H, Voss E, Zimmermann G. 1997. Covalent lipid-phosphonocarboxylic acid conjugates for use as anti-viral agents. DE 19547022.
7. Hostetler KY, Kini GD, Beadle JR. 1996. Lipid prodrugs of pharmaceuticals with improved bioavailability. WO 9639831.
8. Bailey JM, Lightfoote M, Lillehoj E, Nelson K. 1994. Synthesis and antiviral properties of sterol phosphonoformates. Biochem Soc Trans 22(3):353S.
9. Hostetler KY, Kini GD. 1996. Preparation of glycerophospholipids as virucides. WO 9615132.
10. McKenna CE, Li Z, Liu X. 2000. Preparation and use of sulfur-containing phosphonoformate derivatives and analogs. WO 2000002566.
11. Gorin B, Pring B, Thatcher G. 1998. Preparation for phosphonoformic acid derivatives and their use as antiviral agents. WO 9825938.
12. Maloisel J, Pring B, Tiden A. 1998. Preparation of novel glucosyl phosphonoformate esters as virucides. WO 9816537.
13. Noren JO, Helgstrand E, Johansson NG, Misiorny A, Stening G. 1983. Synthesis of esters of phosphonoformic acid and their antiherpes activity. J Med Chem 26(2):264-270.
14. Vlieghe P, Bihel F, Clerc T, Pannecouque C, Witvrouw M, De Clercq E, Salles J, Chermann J, Kraus J. 2001. New 3′-azido-3′ -deoxythimidin-5′-yl O-(ω-hydroxyalkyl) carbonate prodrugs: Synthesis and anti-HIV evaluation. J Med Chem 44:777-786.
15. MacNair RN. 1967. Photochromism in triphenylmethanes. Photochem Photobiol 6:779-797.
16. Falt J, Dahlgren C, Karlsson A, Ahmed AMS, Minnikin DE, Ridell M. 1999. Activation of human neutrophils by mycobacterial phenolic glycolipids. Clin Exp Immunol 188(2):253-260.
17. Lippman RD. 1981. Site-specific chemiluminescent probes used in the analysis of pH, peroxidation and free radicals internally in metabolically active organelles. In: Deluca M, McElroy W, editors. Bioluminescence and chemiluminescence. New York: Academic Press, pp 373-381.
18. Wilkinson F. 1968. Intramolecular electronic energy transfer between organic molecules. In: Bowen EJ, editor. Luminescence in chemistry. London: Van Nostrand Reinhold, Chapter 8, pp 154-182.
19. Morawetz H. 1988. Studies of synthetic polymers by non-radiative energy transfer. Science 240:172-176.
20. Schnepp O, Levy M. 1962. Intramolecular energy transfer in naphthalene-anthracene system. J Am Chem Soc 84:172-177.
21. Roswell DF, White EH. 1978. The chemiluminescence of luminol and related hydrazides. In: Colowick SP, Kaplan NO, editors. Methods in enzymology, Vol. LVII. New York: Academic Press, Chapter 36, pp 409-423.
22. Wardell WM. 1979. Scientific criteria and methods for drug assessment: Requirements in the United States of America. In: Bowers JZ, Velco GP, editors. Drug assessment criteria and methods. Amsterdam: North Holland Biomedical Press, pp 91-101.
23. Miller C, Duncan W. 1997. The 120 million dollar a month pharmaceutical race. Today's Chemist at Work 6(4):50-57.
24. Pearson DE, Buehler CA. 1972. Friedel-Crafts acylations with little or no catalyst. Synthesis 10:533-542.
25. Yamamoto Y, Nishiyama M, Koie Y. 1998. Palladium-catalyzed synthesis of triarylamines from aryl halides and diarylamines. Tetrahedron Lett 39:2367-2370.
26. Schroeder HR, Boguslaski RC, Carrico RJ, Buckler RT. 1978. Monitoring specific protein-binding reactions with chemiluminescence. In: Colowick SP, Kaplan NO, editors. Methods in enzymology, Vol. LVII. New York: Academic Press, Chapter 37, pp 424-445.